Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data

Citius Oncology ( (CTOR) ) has shared an announcement.

On March 10, 2026, Citius Oncology reported positive topline data from a completed investigator-initiated Phase 1 trial led by University of Pittsburgh researchers evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic cancers. The non-chemotherapy dose-escalation study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level.

Among 21 evaluable patients, the trial recorded a 24% objective response rate and a 48% clinical benefit rate, suggesting the LYMPHIR–pembrolizumab regimen may enhance anti-tumor activity in a population with poor prognosis and limited treatment options. While the Phase 1 design was not powered to establish efficacy, the early signal supports further exploration in Phase 2 settings and underscores LYMPHIR’s potential to address a significant unmet need in relapsed or refractory ovarian and endometrial cancers, where current immunotherapies have had limited impact.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Spark’s Take on CTOR Stock

According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, widening losses, and increasing cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting this modestly are positive corporate developments (encouraging Phase 1 data and added funding runway), while valuation remains constrained by continued losses and no dividend.

To see Spark’s full report on CTOR stock, click here.

More about Citius Oncology

Citius Oncology, Inc., a Nasdaq-listed oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, develops and commercializes targeted cancer therapies. The company launched LYMPHIR, an FDA-approved treatment for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, in the U.S. in December 2025, and estimates its initial market opportunity exceeds $400 million in a growing, underserved segment.

Citius Oncology’s competitive positioning is supported by a portfolio of intellectual property protections, including orphan drug designation, complex manufacturing know-how, trade secrets and pending patents for LYMPHIR’s use in immuno-oncology combinations. The company aims to leverage this platform to expand LYMPHIR’s use alongside checkpoint inhibitors and advance additional novel oncology assets for difficult-to-treat cancers.

Average Trading Volume: 375,660

Technical Sentiment Signal: Sell

Current Market Cap: $89.16M

For an in-depth examination of CTOR stock, go to TipRanks’ Overview page.